Large Israeli study shows Pfizer's vaccine cuts symptomatic COVID-19 by 94 percent

Israel vaccinates against COVID-19
(Image credit: Jack Guez/AFP/Getty Images)

Israel has now fully vaccinated 28 percent of its population against COVID-19 and administered the first dose to 42 percent of its nine million inhabitants, and its data is very promising. Clalit, the largest of Israel's four health-care providers, reported Sunday that the Pfizer-BioNTech vaccine has resulted in a 94 percent drop in symptomatic COVID-19 infections among those who have gotten both doses and a 92 percent decline in severe illness.

Clalit compared 600,000 Israelis who have been fully vaccinated against an equal number who have not, pairing vaccinated people and non-vaccinated people with a similar age and health profile. The majority of people studied were age 16 to 59, but 170,000 of the 600,000 Israelis were 60 or older. "It is now unequivocal that Pfizer's vaccine against the coronavirus is incredibly effective in real life one week after the second dose, just as was found in the clinical study," Ran Balicer, Clalit's chief innovation officer and one of the study's authors, said in a statement Sunday. He said the vaccine is even more effective two weeks after the second shot.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.